The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

About Us

What is MRD and when should it be tested?

Danielle Hammond

January 6, 2021

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, Know AML spoke to Danielle Hammond, MD Anderson Cancer Center, Houston, US. We asked, What is measurable residual disease (MRD) and when should it be tested? In this video, after explaining what MRD is, Hammond talks about the different techniques used to assess MRD. She then highlights the importance of MRD assessment at the end of treatment and for at least the first two years after achieving deep remission.